TY - JOUR
T1 - Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma
AU - Sun, Yeping
AU - Eluf-Neto, José
AU - Bosch, F. Xavier
AU - Muñoz, Nubia
AU - Walboomers, Jan M.M.
AU - Meijer, Chris J.L.M.
AU - Shah, Keerti V.
AU - Clayman, Barbara
AU - Viscidi, Raphael P.
PY - 1999/10
Y1 - 1999/10
N2 - Serum samples from 194 cases and 217 controls participating in a case- control study of invasive cervical cancer in Brazil were examined for antibodies to human papillomavirus (HPV) 16 virus-like particles (VLPs) by ELISA. The prevalence of antibody in cases and controls was 47.4 versus 24.4% (P < 0.001). The prevalence was higher in women who had HPV-16 DNA in the genital tract (54.2%) than in those with other HPVs (36.8%) or no HPVs (44.8%), but the differences were not statistically significant. Among cases and controls, HPV-16 VLP antibodies were associated with a greater number of lifetime sexual partners (χ2 for trend, P < 0.001). Among controls, age was inversely associated with HPV-16 VLP seroreactivity (χ2 for trend, P = 0.019). The sera were previously tested for antibodies to HPV-16 E6 and E7 oncoproteins; there was no correlation between antibody titers to HPV-16 E6 or E7 and VLPs. The HPV-16 serological assays were compared as screening tests for invasive cervical cancer. The sensitivity and specificity estimates were 47.4 and 75.6% for HPV-16 VLP serology, 63.4 and 89.9% for either HPV-16 E6 or E7 serology, and 53.6 and 93.6% for high titers of either HPV-16 E6 or E7 or VLP antibodies. The utility of HPV-16 VLP ELISA as a screening test for invasive cervical cancer is limited by a high seroprevalence in women with probable prior exposure to HVP 16 but without disease.
AB - Serum samples from 194 cases and 217 controls participating in a case- control study of invasive cervical cancer in Brazil were examined for antibodies to human papillomavirus (HPV) 16 virus-like particles (VLPs) by ELISA. The prevalence of antibody in cases and controls was 47.4 versus 24.4% (P < 0.001). The prevalence was higher in women who had HPV-16 DNA in the genital tract (54.2%) than in those with other HPVs (36.8%) or no HPVs (44.8%), but the differences were not statistically significant. Among cases and controls, HPV-16 VLP antibodies were associated with a greater number of lifetime sexual partners (χ2 for trend, P < 0.001). Among controls, age was inversely associated with HPV-16 VLP seroreactivity (χ2 for trend, P = 0.019). The sera were previously tested for antibodies to HPV-16 E6 and E7 oncoproteins; there was no correlation between antibody titers to HPV-16 E6 or E7 and VLPs. The HPV-16 serological assays were compared as screening tests for invasive cervical cancer. The sensitivity and specificity estimates were 47.4 and 75.6% for HPV-16 VLP serology, 63.4 and 89.9% for either HPV-16 E6 or E7 serology, and 53.6 and 93.6% for high titers of either HPV-16 E6 or E7 or VLP antibodies. The utility of HPV-16 VLP ELISA as a screening test for invasive cervical cancer is limited by a high seroprevalence in women with probable prior exposure to HVP 16 but without disease.
UR - http://www.scopus.com/inward/record.url?scp=0032707991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032707991&partnerID=8YFLogxK
M3 - Article
C2 - 10548324
AN - SCOPUS:0032707991
VL - 8
SP - 935
EP - 940
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 10
ER -